Ciprofloxacin resistant campylobacter

Risk factors for ciprofloxacin-resistant Campylobacter infection in Wales.

OBJECTIVES To identify risk factors for ciprofloxacin resistance in both travel-related and domestically acquired Campylobacter infection. METHODS Case-comparison study of patients with ciprofloxacin-resistant and ciprofloxacin-susceptible Campylobacter infection conducted in Wales during 2003 and 2004. RESULTS Foreign travel was the major risk factor for ciprofloxacin-resistant infection [...

Ciprofloxacin-Resistant Campylobacter spp. in Retail Chicken, Western Canada

During 2005-2010, the Canadian Integrated Program for Antimicrobial Resistance Surveillance identified increased prevalence of ciprofloxacin (a fluororquinolone) resistance among Campylobacter isolates from retail chicken in British Columbia (4%-17%) and Saskatchewan (6%-11%), Canada. Fluoroquinolones are critically important to human medicine and are not labeled for use in poultry in Canada.

Prolonged diarrhea due to ciprofloxacin-resistant campylobacter infection.

BACKGROUND Campylobacter causes >1 million infections annually in the United States. Fluoroquinolones (e.g., ciprofloxacin) are used to treat Campylobacter infections in adults. Although human infections with ciprofloxacin-resistant Campylobacter have become increasingly common, the human health consequences of such infections are not well described. METHODS A case-control study of persons wi...

Ciprofloxacin resistant Neisseria gonorrhoeae.

High genetic similarity of ciprofloxacin-resistant Campylobacter jejuni in central Europe

Campylobacteriosis is the leading zoonosis in the European Union with the majority of cases attributed to Campylobacter jejuni. Although the disease is usually self-limiting, some severe cases need to be treated with antibiotics, primarily macrolides and quinolones. However, the resistance to the latter is reaching alarming levels in most of the EU countries. To shed light on the expansion of a...